Skip to main content

Celera Genomics Licenses Cancer Targets from Proteomics Effort to Genentech

NEW YORK, Sept. 28 (GenomeWeb News) - Celera Genomics and Genentech have signed a multi-year agreement to develop new cancer drugs based on targets derived from Celera's proteomics platform, Celera said today.

 

Celera will license to Genentech a number of cell-surface targets that it discovered and validated using its proteomics platform. Genentech plans to validate these further and develop drugs against them. These drugs could be antibodies, antibody fragments, proteins, or small molecule drugs.

 

Celera Genomics will receive progess-dependent milestone payments and royalties on sales of any drugs developed. Celera Diagnostics retains the rights to develop certain diagnostics based on the targets.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.